Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares. AI is about to change ...

Altimmune's stock, which was added to the Nasdaq Biotechnology Index (NBI) in December, has a short interest of 28.2%, ...

Meeting to be held in Boston on April 9 and in New York on April 10 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

Altimmune has had a history of failing to launch or coming up short, like its adCOVID vaccine, which flunked its Phase 1 clinical trials by failing to produce an adequate immune response in 2021.

HC Wainwright reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research report sent to ...

The last time I wrote an article on Altimmune, Inc. (NASDAQ:ALT) it was in a Seeking Alpha article entitled "Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge." In this article ...

Schroder Investment Management Group lessened its position in Altimmune, Inc. (NASDAQ:ALT – Free Report) by 9.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm ...

Bullish option flow detected in Altimmune (ALT) with 8,561 calls trading, 3x expected, and implied vol increasing almost 4 points to 114.21%.

In the last three months, 8 analysts have published ratings on Altimmune (NASDAQ:ALT), offering a diverse range of perspectives from bullish to bearish. The table below provides a concise overview ...

In this article, we will see how Altimmune, Inc. (NASDAQ:ALT) compares to the other top short squeeze stocks that have received a Buy rating from analysts. Stock market trading has an ever ...

Claim your 7-day free trial now. Altimmune Inc ALT hosted a virtual R&D day on Thursday, marking the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential ...